Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Payables: 2018-2025

Historic Payables for China SXT Pharmaceuticals (SXTC) over the last 8 years, with Mar 2025 value amounting to $8.0 million.

  • China SXT Pharmaceuticals' Payables rose 17.93% to $976,367 in Q3 2025 from the same period last year, while for Sep 2025 it was $11.5 million, marking a year-over-year increase of 161.65%. This contributed to the annual value of $8.0 million for FY2025, which is 349.63% up from last year.
  • According to the latest figures from FY2025, China SXT Pharmaceuticals' Payables is $8.0 million, which was up 349.63% from $1.8 million recorded in FY2024.
  • China SXT Pharmaceuticals' Payables' 5-year high stood at $8.0 million during FY2025, with a 5-year trough of $1.5 million in FY2023.
  • Its 3-year average for Payables is $3.8 million, with a median of $1.8 million in 2024.
  • Per our database at Business Quant, China SXT Pharmaceuticals' Payables tumbled by 56.22% in 2023 and then skyrocketed by 349.63% in 2025.
  • Yearly analysis of 5 years shows China SXT Pharmaceuticals' Payables stood at $3.1 million in 2021, then climbed by 14.44% to $3.5 million in 2022, then slumped by 56.22% to $1.5 million in 2023, then grew by 14.71% to $1.8 million in 2024, then soared by 349.63% to $8.0 million in 2025.